GlassScriptPhysician profile
Sara Kilgore
NPI 1851063994
$4,019.37
in general payments reported to CMS, 2019-2025
45 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $762 · 2023: $161 · 2024: $1,816 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,062 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,062.25 |
| Education | $194.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $660.00 | 2022 | |
| Merck Sharp & Dohme LLC | $305.97 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $304.73 | 2024-2025 | |
| Pfizer INC. | $252.77 | 2024-2025 | |
| Abbvie INC. | $219.84 | 2024-2025 | |
| Daiichi Sankyo INC. | $212.98 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $191.28 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $178.60 | 2023-2025 | Opdivo, Opdualag, Augtyro |
| Eisai INC. | $161.85 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.13 | 2023-2025 | Fruzaqla, Iclusig, Alunbrig |
| Genentech USA, INC. | $83.05 | 2023-2025 | Polivy, Columvi, Lunsumio |
| Genmab U.S., INC. | $73.44 | 2024-2025 | Tivdak, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $70.92 | 2025 | |
| Servier Pharmaceuticals LLC | $65.65 | 2024-2025 | |
| Janssen Biotech, INC. | $65.49 | 2023-2024 | Tecvayli, Talvey, Erleada |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62.29 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $54.76 | 2024-2025 | Xospata |
| Pharmaessentia USA Corporation | $54.50 | 2024-2025 | Besremi |
| Taiho Oncology, INC. | $50.96 | 2024 | |
| Tersera Therapeutics LLC | $50.34 | 2025 | Xermelo, Zoladex |
| Deciphera Pharmaceuticals INC. | $49.99 | 2023-2025 | Qinlock, Romvimza |
| Geron Corporation | $49.60 | 2024-2025 | Rytelo |
| Beigene USA, INC. | $47.22 | 2024-2025 | Brukinsa |
| Adc Therapeutics America, INC. | $45.98 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $45.94 | 2024-2025 | |
| Beone Medicines USA, INC. | $44.16 | 2025 | Brukinsa, Tevimbra |
| Tempus Ai, INC | $43.10 | 2024 | Xt Cdx |
| Gilead Sciences, INC. | $42.11 | 2024-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $41.87 | 2024-2025 | Xpovio |
| Lilly USA, LLC | $40.53 | 2024 | Verzenio, Retevmo, Jaypirca |
| Exelixis INC. | $35.93 | 2024-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $34.66 | 2024 | |
| Pharmacosmos Therapeutics INC. | $33.37 | 2024-2025 | Cosela, Monoferric |
| Array Biopharma INC | $29.46 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Alexion Pharmaceuticals, INC. | $26.43 | 2024 | Ultomiris |
| Dendreon Pharmaceuticals LLC | $25.12 | 2024 | Provenge |
| Sumitomo Pharma America, INC. | $23.11 | 2025 | Orgovyx |
| Sobi, INC | $22.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.52 | 2024 | |
| Sun Pharmaceutical Industries INC. | $19.29 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.40 | 2022 | |
| Acrotech Biopharma INC. | $18.30 | 2024 | Beleodaq |
| Apellis Pharmaceuticals, INC. | $18.08 | 2023 | Empaveli |
| Genzyme Corporation | $15.22 | 2022 | |
| Incyte Corporation | $13.67 | 2025 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Kilgore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.